Intervention: FLUTICASONE PROPIONATE
Trial phase: Phase 3
ATC code: D07AC17 | R01AD08 | R01AD58 | R03BA05
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@@]21C
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 450
Group description: fluticasone propionate nasal spray
Eligibility criteria:
Inclusion Criteria:

Male/female subjects 12 years of age and older
Provide written informed consent/pediatric assent.

Subjects must have moderate-to-severe rhinitis, with one or more of the following present:

Sleep disturbance
Impairment of daily activities, leisure and/or sport
Impairment of school or work
Troublesome symptoms
Screening Visit: Have a 12-hour reflective TNSS of at least 8 out of a possible 12 and a congestion score of 2 or 3 on Visit 1
Randomization Visit: For the 3 days prior to Randomization and on the morning of Randomization, the sum of the 7 consecutive reflective AM and PM TNSS assessments shall be equal to or greater than 56, with a nasal congestion score equal to or greater than 14
Randomization Visit: instantaneous TNSS score of at least 8 and a congestion score of at least 2 just prior to beginning the onset of action assessment
Have taken at least 10 doses of the lead-in medication
Willing and able to comply with the study requirements
At least a 2-year history of SAR during the current allergy season
The presence of IgE-mediated hypersensitivity to a prevailing, individual, seasonal pollen, confirmed by a positive response to skin prick within the last year.
General good health and free of any disease or concomitant treatment that could interfere with the interpretation of the study results.
Subjects receiving immunotherapy injections (antigen desensitization) must be on a stable maintenance regimen for at least 30 days before the first study visit
Subjects currently receiving sublingual immunotherapy are excluded. A 6-month washout period is required following the last dose of sublingual immunotherapy.

Exclusion Criteria:

On Focused Nasal Examination, the presence of any superficial and moderate nasal mucosal erosion, nasal mucosal ulceration, or nasal septum perforation (Grade 1b - 4) at either the screening visit or randomization visit will disqualify the subject from the study.
Other nasal disease(s) likely to affect deposition of intranasal medication.
Nasal surgery or sinus surgery within the previous year.
Chronic sinusitis - more than 3 episodes per year
Planned travel outside of the pollen area during the study period
The use of any investigational drug within 30 days prior to Visit 1. No investigational products are permitted for use during the conduct of this study
Presence of any hypersensitivity to drugs similar to azelastine hydrochloride or fluticasone propionate
Women who are pregnant or nursing
Women of childbearing potential who are not abstinent or not practicing a medically acceptable method of contraception* see section 6.1.1
Respiratory Tract Infections within 14 days prior to Visit 1
Respiratory Tract Infections requiring antibiotic treatment 14 days prior to Visit 1
Asthma (with the exception of intermittent asthma).
Significant pulmonary disease including COPD
Clinically significant arrhythmia or symptomatic cardiac conditions
A known history of alcohol or drug abuse within the last 2 years
Existence of any surgical or medical condition or physical or laboratory findings, might significantly alter the absorption, distribution, metabolism, or excretion of study drug; that might significantly affect the subject's ability to complete this trial; or their safety in this trial.
Patients with a history of glaucoma
Clinically relevant abnormal physical findings within 1 week of randomization may preclude compliance with the study procedures
Employees of the research center or private practice and their family members
no more than 50% of their subjects have participated in protocol MP4001, MP4002 or MP4004